CYSLTR1 and allergic rhinitis: Montelukast is a selective antagonist of CYSLTR1, which can ameliorate leukotriene (LTD)-induced bronchoconstriction and significantly reduce both the early and late airway responses to allergens, rendering it effective against allergic rhinitis and asthma.